Clinical Trials Browser

Lymphoma, Follicular × loncastuximab tesirine × Clear all

NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04998669 2026-03-23

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT07197307 2025-09-29

CLEAR

Phase 2 Not yet recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04699461 2023-10-23

LOTIS-6

Phase 2 Terminated

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1 Terminated

13 enrolled 15 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Phase 1 Completed

183 enrolled 38 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell